A statement released earlier today by Barclays Capital about Charles River Laboratories (NYSE:CRL) ups the target price to $77.00
- Updated: November 30, 2016
Yesterday Charles River Laboratories (NYSE:CRL) traded 2.07% higher at $71.27. The company’s 50-day moving average is $76.01 and its 200-day moving average is $81.84. The last closing price is down -10.75% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 11,698 shares of the stock traded hands, down from an average trading volume of 460,870
Stating a potential upside of 0.08%, Barclays Capital bumped up the stock price target of Charles River Laboratories (NYSE:CRL) to $77.00
Previously on Thursday February 11, 2016, UBS Securities reported on Charles River Laboratories (NYSE:CRL) increased the target price from $75.00 to $76.00. At the time, this indicated a possible upside of 0.07%.
See Chart Below
Charles River Laboratories has a 52 week low of $65.70 and a 52 week high of $89.18 with a P/E ratio of 24.68 The company’s market cap is currently $0.
In addition to Barclays Capital reporting its stock price target, a total of 15 brokers have issued a research note on the company. The average stock price target is $85.47 with 6 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 8 brokers rating the stock a hold, 2 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Charles River Laboratories (NYSE:CRL)
Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.